Steven D Forsythe
Overview
Explore the profile of Steven D Forsythe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andrews S, Forsythe S, Madigan J, Sadowski S
Endocr Oncol
. 2024 Dec;
4(1):e240038.
PMID: 39649120
Small intestinal neuroendocrine tumors, siNETs, are a group of rare cancers that arise from neuroendocrine cells in the lining of the jejunum and ileum, which are either classified as tumors,...
2.
Johansen A, Forsythe S, McGrath C, Barker G, Jimenez H, Paluri R, et al.
Clin Cancer Res
. 2024 Jun;
30(17):3676-3687.
PMID: 38916900
TGFβ is a pleiotropic signaling pathway that plays a pivotal role in regulating a multitude of cellular functions. TGFβ has a dual role in cell regulation where it induces growth...
3.
Enhancing the Efficacy of HIPEC Through Bromelain: A Preclinical Investigation in Appendiceal Cancer
Wajih N, Erali R, Forsythe S, Schaaf C, Shen P, Levine E, et al.
Ann Surg Oncol
. 2024 May;
31(8):5377-5389.
PMID: 38704503
Introduction: Appendiceal cancer (AC) excessive mucin production is a barrier to heated intraperitoneal chemotherapy (HIPEC) drug delivery. Bromelain is a pineapple stem extract with mucolytic properties. We explored bromelain treatment...
4.
Forsythe S, Pu T, Andrews S, Madigan J, Sadowski S
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568572
Pancreatic neuroendocrine neoplasms (pNENs) are a heterogeneous group of tumors derived from multiple neuroendocrine origin cell subtypes. Incidence rates for pNENs have steadily risen over the last decade, and outcomes...
5.
Forsythe S, Erali R, Edenhoffer N, Meeker W, Wajih N, Schaaf C, et al.
Sci Rep
. 2023 Jul;
13(1):11640.
PMID: 37468581
Peritoneal mesothelioma (PM) is a rare malignancy with poor prognosis, representing about 10-15% of all mesothelioma cases. Herein we apply PM patient-derived tumor organoids (PTOs) in elucidating personalized HIPEC responses...
6.
Valenzuela C, Solsky I, Erali R, Forsythe S, Mangieri C, Mainali B, et al.
Ann Surg Oncol
. 2023 Feb;
30(5):2666-2675.
PMID: 36754945
Background: Malignant peritoneal mesothelioma (MPM) is a rare diagnosis with a dismal prognosis if untreated. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is shown to significantly improve survival. Our institution...
7.
Erali R, Forsythe S, Gironda D, Schaaf C, Wajih N, Soker S, et al.
J Gastrointest Cancer
. 2022 Nov;
54(3):712-719.
PMID: 36447085
Introduction: Treatment of colorectal cancer-derived peritoneal carcinomatosis (CRC-PC) is challenging due to cellular heterogeneity that exhibits variable degrees of resistance to systemic as well as intraperitoneal chemotherapy. Therefore, it is...
8.
Forsythe S, Erali R, Laney P, Sivakumar H, Li W, Skardal A, et al.
Sci Rep
. 2022 Aug;
12(1):13865.
PMID: 35974123
Merkel cell carcinoma (MCC) is a rare neuroendocrine cutaneous cancer, with incidence of less than 1/100,000, low survival rates and variable response to chemotherapy or immunotherapy. Herein we explore the...
9.
Forsythe S, Sivakumar H, Erali R, Wajih N, Li W, Shen P, et al.
Ann Surg Oncol
. 2022 Jul;
29(12):7354-7367.
PMID: 35780216
Introduction: Sarcoma clinical outcomes have been stagnant for decades due to heterogeneity of primaries, lack of comprehensive preclinical models, and rarity of disease. We hypothesized that engineering hydrogel-based sarcoma organoids...
10.
Forsythe S, Sivakumar H, Erali R, Skardal A, Votanopoulos K
Ann Surg Oncol
. 2022 Jul;
29(12):7368-7369.
PMID: 35778628
No abstract available.